Highlight
– Direct oral anticoagulants (DOACs) showed a higher 1-year risk of ischemic and composite stroke compared to warfarin in patients with atrial fibrillation and mitral stenosis (AF-MS).
– DOACs were associated with a lower risk of myocardial infarction at 1 year.
– No significant difference was found between DOACs and warfarin regarding bleeding complications or all-cause mortality.
– Rivaroxaban, a specific DOAC, was linked to increased ischemic stroke risk in both short- and long-term follow-up.
